Search

everythinglearnresearchcommunity

for

Search:↓

The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.

Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.

Suppressing certain hormones might help prevent prostate cancer.

Mutations in certain receptors can cause diseases and offer new treatment options.

Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.

Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

Taking spironolactone doesn't increase the chance of breast cancer coming back.

Androgens increase cervical cancer risk and affect its development.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Bald men may have a lower risk of testicular cancer.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Androgenetic alopecia may indicate higher risk for certain diseases and mental health issues.

A new method helps manage skin side effects from hormonal cancer therapy, improving patient care.

Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.

The issue covers reproductive health topics like cancer markers, incontinence treatments, and the impact of pre-term birth.